EUVIMEDEUVIMED entdecken
Crossref

Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon

Joshua R. Niska, Nathan Y. Yu, Jean-Claude M. Rwigema, Sarah E. James, Brady S. Laughlin, Carlos E. Vargas, Steven E. Schild

AME Clinical Trials Review · 2026-06 · 4 · 29-29

DOI: 10.21037/actr-25-133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Joshua R. Niska und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Niska, J. R., Yu, N. Y., Rwigema, J. M., James, S. E., Laughlin, B. S., Vargas, C. E., & Schild, S. E. (2026). Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon. AME Clinical Trials Review, 4, 29-29. https://doi.org/10.21037/actr-25-133

Vancouver

Niska JR, Yu NY, Rwigema JM, James SE, Laughlin BS, Vargas CE, et al. Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon. AME Clinical Trials Review. 2026;4:29-29. doi:10.21037/actr-25-133

BibTeX
@article{Niska2026,
  author = {Niska, Joshua R. and Yu, Nathan Y. and Rwigema, Jean-Claude M. and James, Sarah E. and Laughlin, Brady S. and Vargas, Carlos E. and Schild, Steven E.},
  title = {Androgen deprivation therapy and definitive radiotherapy for intact prostate cancer in the modern era: personalized medicine on the horizon},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {29--29},
  doi = {10.21037/actr-25-133}
}
Kostenlos starten →